Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863466 | 0.82 | POLB (0.48) | POLBHSP90AA1HSP90AB1KMT2A | |
| SCHEMBL26789473 | 0.79 | POLB (0.59) | POLBHSP90AA1HSP90AB1KMT2AALDH1A1 | |
| SCHEMBL21383369 | 0.78 | KMT2A (0.55) | POLBHSP90AA1HSP90AB1KMT2AALDH1A1 | |
| SCHEMBL3268236 | 0.77 | KMT2A (0.57) | POLBHSP90AA1HSP90AB1KMT2AALDH1A1 | |
| SCHEMBL26091092 | 0.76 | POLB (0.47) | POLBHSP90AA1HSP90AB1KMT2AALDH1A1 | |
| SCHEMBL18381330 | 0.73 | MEN1 (0.43) | POLBKMT2AALDH1A1GAAMEN1 | |
| SCHEMBL49946 | 0.73 | KMT2A (0.57) | POLBHSP90AA1HSP90AB1KMT2AALDH1A1 | |
| SCHEMBL9523223 | 0.72 | KMT2A (0.55) | POLBHSP90AA1HSP90AB1KMT2AALDH1A1 | |
| SCHEMBL19059738 | 0.71 | SMN1; SMN2 (0.42) | KMT2AGAAMEN1KDM4EMAPK1 | |
| SCHEMBL2632922 | 0.70 | KMT2A (0.62) | POLBHSP90AA1HSP90AB1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | POLB 3885/4885HSP90AA1 769/4885HSP90AB1 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.